MA55592A - Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1 - Google Patents
Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1Info
- Publication number
- MA55592A MA55592A MA055592A MA55592A MA55592A MA 55592 A MA55592 A MA 55592A MA 055592 A MA055592 A MA 055592A MA 55592 A MA55592 A MA 55592A MA 55592 A MA55592 A MA 55592A
- Authority
- MA
- Morocco
- Prior art keywords
- glp
- formula
- receptor agonists
- including compounds
- therapy including
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305468 | 2019-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55592A true MA55592A (fr) | 2022-02-16 |
Family
ID=66334312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055592A MA55592A (fr) | 2019-04-10 | 2020-04-09 | Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220362187A1 (fr) |
EP (1) | EP3952855A1 (fr) |
JP (1) | JP2022528549A (fr) |
KR (1) | KR20210150436A (fr) |
CN (1) | CN113677336B (fr) |
BR (1) | BR112021020234A2 (fr) |
CA (1) | CA3130718A1 (fr) |
MA (1) | MA55592A (fr) |
TW (1) | TW202103694A (fr) |
WO (1) | WO2020208205A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113855812B (zh) * | 2021-12-01 | 2022-03-11 | 上海翰森生物医药科技有限公司 | 聚乙二醇洛塞那肽或其药物组合物的新医药用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2641596T3 (en) * | 2009-11-26 | 2018-08-06 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for the treatment of liver disorders |
RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
CN107106873A (zh) * | 2015-01-09 | 2017-08-29 | 吉利德阿波罗公司 | 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 |
BR112017016766B1 (pt) * | 2015-02-06 | 2023-11-07 | Intercept Pharmaceuticals, Inc | Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática |
EP3349751A4 (fr) * | 2015-09-16 | 2019-05-22 | Tobira Therapeutics, Inc. | Polythérapie faisant appel au cénicriviroc pour le traitement de la fibrose |
CA3047862A1 (fr) * | 2016-12-22 | 2018-06-28 | Sanofi | Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise |
SG11201906987RA (en) * | 2017-02-21 | 2019-09-27 | Genfit | Combination of a ppar agonist with a fxr agonist |
BR112019021910A2 (pt) * | 2017-04-18 | 2020-05-26 | Genfit | Combinação de elafibranor ou derivados do mesmo com um agente anti-nash, antifibrótico ou anticolestático |
-
2020
- 2020-04-09 MA MA055592A patent/MA55592A/fr unknown
- 2020-04-09 CN CN202080026213.5A patent/CN113677336B/zh active Active
- 2020-04-09 BR BR112021020234A patent/BR112021020234A2/pt unknown
- 2020-04-09 WO PCT/EP2020/060283 patent/WO2020208205A1/fr unknown
- 2020-04-09 KR KR1020217034881A patent/KR20210150436A/ko unknown
- 2020-04-09 CA CA3130718A patent/CA3130718A1/fr active Pending
- 2020-04-09 JP JP2021559868A patent/JP2022528549A/ja active Pending
- 2020-04-09 EP EP20717202.4A patent/EP3952855A1/fr active Pending
- 2020-04-09 US US17/602,296 patent/US20220362187A1/en active Pending
- 2020-04-10 TW TW109112117A patent/TW202103694A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022528549A (ja) | 2022-06-14 |
CA3130718A1 (fr) | 2020-10-15 |
TW202103694A (zh) | 2021-02-01 |
EP3952855A1 (fr) | 2022-02-16 |
CN113677336A (zh) | 2021-11-19 |
CN113677336B (zh) | 2024-04-30 |
US20220362187A1 (en) | 2022-11-17 |
WO2020208205A1 (fr) | 2020-10-15 |
BR112021020234A2 (pt) | 2021-12-07 |
KR20210150436A (ko) | 2021-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3413B1 (ar) | مشتقات نافثيريدين في صورة مضادات ألفا v بيتا 6 إنتيجرين لعلاج الأمراض الليفية e.g | |
EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
DOP2015000308A (es) | Inhibidores de bromodominios | |
EA201400567A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
EA201201541A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ | |
CO7310529A2 (es) | Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory | |
EA201000046A1 (ru) | Замещенные имидазогетероциклы | |
PE20161343A1 (es) | Benzamidas sustituidas para el tratamiento de artropodos | |
MA38540B1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
ATE533762T1 (de) | Chinolin- oder isochinolinsubstituierte p2x7- antagonisten | |
MA31118B1 (fr) | Procede de preparation d'un derive de benzimidazole | |
EA200801001A1 (ru) | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине | |
MA39753B1 (fr) | Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues | |
BR112019008656A2 (pt) | composto de aminopirazolopirimidina usado como inibidor de receptor de tirosina quinase de fator neurotrófico | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
EA201171062A1 (ru) | Алкиламидные соединения и их применение | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
MA55592A (fr) | Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1 | |
CO2022008313A2 (es) | Compuestos químicos | |
MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. |